NCT02014480 - A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

February 1, 2013

Primary Completion Date

June 1, 2013

Study Completion Date

June 11, 2013

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

Umeclidinium 62.5 mcg

Umeclidinium 62.5 mcg once daily in the morning via NDPI.

DEVICE

Vilanterol 25 mcg

Vilanterol 25 mcg once daily in the morning via NDPI.

DEVICE

Umeclidinium/Vilanterol 62.5/25 mcg

Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.

Trial Locations (21)

21018

GSK Investigational Site, Vinnytsia

21029

GSK Investigational Site, Vinnytsia

36024

GSK Investigational Site, Poltava

54003

GSK Investigational Site, Mykolayiv

61035

GSK Investigational Site, Kharkiv

76018

GSK Investigational Site, Ivano-Frankivsk

83003

GSK Investigational Site, Donetsk

83099

GSK Investigational Site, Donetsk

95017

GSK Investigational Site, Sympheropol

95043

GSK Investigational Site, Simferopol

066 01

GSK Investigational Site, Humenné

077 01

GSK Investigational Site, Kráľovský Chlmec

058 01

GSK Investigational Site, Poprad

927 01

GSK Investigational Site, Šaľa